AddedRisk Factors
The ability of the FDA to review and approve regulatory submissions can be affected by a variety of factors, including statutory, regulatory and policy changes, inadequate government budget funding levels or a reduction in the FDA’s workforce and its ability to hire and retain key personnel, disruptions caused by government shutdowns, public health crises, the FDA’s ability to accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform routine functions. There have been mass layoffs of federal employees since the start of the current presidential administration in January 2025, the full impact of which is unclear at this time. Such disruptions could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. For example, during the U.S. government shut down in October 2025, the FDA was not able to accept applications for new drugs, generics, biologics, biosimilars or medical devices that require payment of a user fee. In addition, the presidential administration has made and is expected to continue to make changes in the leadership of various U.S. federal regulatory agencies and changes to U.S. federal government policy that have led to, in some cases, legal challenges and uncertainty around the funding, functioning and policy priorities of the U.S. federal regulatory agencies, including the FDA.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
We are unable to predict the extent to which the presidential administration may impose or seek to impose leadership or policy changes at the FDA or changes to rules and policies impacting our business and operations. It is unclear how these executive actions or other potential actions by the federal government will impact the FDA or other regulatory authorities that oversee our business. Government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA and other related government agencies. These budgetary pressures may reduce the FDA’s ability to perform its responsibilities, which could result in delays in our clinical trial timelines. If a significant reduction in the FDA’s workforce occurs or the FDA’s budget is significantly reduced, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions or take other actions critical to the development or approval of our product candidates, and any delay in the acceptance, review or approval of our investigational new drug applications, clinical trial applications, marketing applications, facility inspections or lot-release/testing activities, could delay or increase the cost of our clinical trials and product launches, if any, which could have a material adverse effect on our business.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
nations and to facilitate direct-to-consumer purchasing programs. The HHS subsequently issued guidance indicating the MFN target price is the lowest price paid in an Organization for Economic Co-operation and Development country with a GDP per capita of at least 60% of the U.S. GDP per capita. It is currently unclear whether and to what extent these measures will be implemented and what impact any such implementation would have on our business. Further, there can be no assurance that the current administration or future administrations will not pursue different or additional measures that could impact drug pricing in the United States. Political, economic and regulatory developments may further complicate developments in healthcare systems and pharmaceutical drug pricing. These developments could, for example, impact our potential licensing agreements as commercial and collaborative partners may also consider the impact of these pressures on their licensing strategies.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedRisk Factors
We cannot be sure that, if our clinical trials for any of our product candidates are successfully completed, we or our collaborators will be able to submit an NDA to the FDA or that any NDA we or our collaborators submit will be approved by the FDA in a timely manner, if at all. In July 2025, Johnson & Johnson filed an NDA with the FDA for the approval of Icotyde for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis and in January 2026, we and Takeda filed an NDA with the FDA for the approval of rusfertide for the treatment of adults with PV.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedRisk Factors
Under the terms of the Takeda Collaboration Agreement, Takeda may terminate the agreement for convenience in its entirety or as to a major region by providing advance written notice following the earliest of (i) the receipt of Phase 3 data with respect to the VERIFY clinical trial, (ii) the third anniversary of the effective date of the agreement or (iii) the occurrence of certain specified adverse events related to the clinical development of rusfertide.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedRisk Factors
commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future revenue will be materially and adversely impacted.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedRisk Factors
developments may further complicate developments in healthcare systems and pharmaceutical drug pricing. These developments could, for example, impact our potential licensing agreements as commercial and collaborative partners may also consider the impact of these pressures on their licensing strategies.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedRisk Factors
around the world has increased. If we are unable to prevent such cybersecurity incidents or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedRisk Factors
financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, which would require additional financial and management resources.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RewordedRisk Factors
If we are not able to comply with the requirements of Section 404 or if we or our independent registered public accounting firm are unable to attest to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, which would require additional financial and management resources.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Accordingly, the likelihood of our success must be evaluated in light of many potential challenges and variables associated with a clinical-stage biopharmaceutical company, many of which are outside of our control, and past results, including operating or financial results, should not be relied on as an indication of future results.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Raising If we require additional capital capital, there may cause be dilution to our existing stockholders, restrict our operations may be restricted, or require us we may be required to relinquish rights to our product candidates or technologies.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the JNJ License and Collaboration Agreement or the Takeda Collaboration Agreement is are terminated early, or if JNJ’s or Takeda’s development activities are terminated early or suspended for an extended period of time, or are otherwise unsuccessful, or if JNJ’s or Takeda’s commercialization efforts are deprioritized or unsuccessful, our business business, financial condition and business prospects would be materially and adversely affected.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are subject to the risk of possible disagreements with JNJ regarding the development or commercialization of icotrokinra Icotyde, if approved, or other matters under the JNJ License and Collaboration Agreement and with Takeda regarding the development or commercialization of rusfertide rusfertide, if approved, or other matters under the Takeda Collaboration Agreement, such as the interpretation of such agreement agreements, milestones or royalty payments or ownership of proprietary rights.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We do not currently have, nor do we plan to develop, the infrastructure or capability internally to manufacture our drug supplies and we expect to continue to depend on contract manufacturers for the foreseeable future.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result of this volatility, payouts under, as well as the incentive value of, our stock-based compensation arrangements for employees can fluctuate and investors may experience losses on their investment in our common stock, including due to the factors discussed in these “Risk Factors” and elsewhere in this Annual Report.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Those trials, such as our ongoing VERIFY Phase 3 trial evaluating trials of Icotyde and rusfertide for the treatment of PV or subsequent late-stage product candidates, may not demonstrate the safety and efficacy of our product candidates for certain indications to support a marketing approval in the United States or other jurisdictions.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Also, because the period of collaborative development under the agreement has ended, JNJ has sole decision-making authority for product candidates resulting from the collaboration, which could lead to disputes with JNJ. decision-
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our operations to date have been limited to developing our technology, undertaking pre-clinical studies and clinical trials of our pipeline candidates and candidates, conducting research to identify additional product candidates and entering into partnerships with collaborators for certain of our product candidates.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
If ay any product candidates we may develop in the future are approved but fail to achieve an adequate level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient revenue revenue, either directly or through milestone and royalty payments from our collaborators, to become or remain profitable.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We have incurred a cumulative net loss since our inception and anticipate that we may incur significant losses in the future.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As a result, we expect to may continue to incur losses in the future as we continue our development of, and seek regulatory approvals for, our product candidates.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If In addition, if any of our product candidates fail in clinical trials or do not gain regulatory approval or fail to achieve market acceptance, we may never become profitable.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Revenue we generate from our collaborations with JNJ, Takeda, and any future collaboration arrangements arrangements, if any, may not be sufficient to sustain our operations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
We are an integrated discovery and development company with a validated technology platform. Our programs fall into three broad therapeutic areas: (i) inflammation and immunology (“I&I”), (ii) hematology and (iii) metabolic diseases. Our aim is to develop medicines for biologically and commercially validated targets which demonstrate a strong differentiation compared to existing therapies.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Icotyde™ (icotrokinra) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which underpins the inflammatory response in psoriasis and offers potential in other IL-23-mediated diseases. Icotyde is licensed to Janssen Biotech, Inc., a Johnson & Johnson company (“JNJ”), under a license and collaboration agreement initially entered into in 2017. Following Icotyde’s joint discovery by Protagonist and JNJ scientists, pursuant to the license and collaboration agreement, we were primarily responsible for the development of Icotyde through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. In July 2025 and September 2025, respectively, JNJ submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) and an application to the European Medicines Agency (“EMA”) seeking the first approval of Icotyde for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis. JNJ has disclosed that it expects to launch Icotyde in the United States in 2026, subject to regulatory approval.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Rusfertide is a first-in-class investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (“PV”). We discovered rusfertide, advanced it into Phase 3 development, and in early 2024 entered into a co-development and co-commercialization arrangement with Takeda Pharmaceuticals, Inc. (“Takeda”) under a license and collaboration agreement entered into in January 2024. We remained primarily responsible for clinical development activities through rusfertide’s NDA filing for the treatment of erythrocytosis in patients with PV, which we and Takeda submitted in December 2025. Rusfertide has also received Orphan Drug status, Fast Track designation and, in August 2025, Breakthrough Therapy designation (“BTD”). BTD is a process designed to expedite the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. BTD also provides eligibility for priority NDA review, and Orphan Drug status qualifies sponsors for various incentives, including the potential for extended market exclusivity. Takeda has disclosed that it expects to launch rusfertide in the second half of 2026, subject to regulatory approval.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, the first human subject was dosed in our Phase 1 trial of PN-881 (ClinicalTrials.gov identifier NCT07153146) evaluating its safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults. Results of the PN-881 Phase 1 study are expected to inform the design and dosing in a subsequent dose-ranging psoriasis trial. We expect to complete the Phase 1 study in mid-2026 and initiate a Phase 2 study of PN-881 in psoriasis by the end of 2026.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
PN-477. In June 2025, we nominated PN-477, a potential best-in-class novel triple GLP-1, GIP and GCG receptor agonist peptide with oral (“PN-477o”) and subcutaneous (“PN-477sc”) routes of administration, as a development candidate for the treatment of obesity. We designed PN-477 to offer an optimal combination of total body weight loss, improved gastrointestinal tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration. IND-enabling studies of PN-477 are underway and the initiation of Phase 1 clinical studies in PN-477sc and PN-477o are anticipated by mid-2026 and in the second half of 2026, respectively.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
PN-458. In December 2025, we nominated development candidate PN-458, a potential best-in-class novel dual GLP-1 and GIP receptor agonist peptide, as a development candidate for the treatment of obesity, with optionality for both an oral (“PN-458o”) and subcutaneous (“PN-458sc”) formulation. IND-enabling studies for PN-458o and PN-458sc are ongoing.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
We ended fiscal 2025 with cash, cash equivalents and marketable securities of approximately $646.0 million, as compared to cash, cash equivalents and marketable securities of approximately $559.2 million as of December 31, 2024. In 2026 and beyond, we are eligible to receive significant milestone, royalty and other payments from our collaborations with JNJ and Takeda, as described below. The receipt of future royalties and commercial milestones is contingent upon the relevant products receiving FDA approval and achieving a successful commercial launch.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
We and JNJ are parties to a license and collaboration agreement related to the development and commercialization of Icotyde. We entered into the agreement in July 2017, and amended it in May 2019, July 2021 and November 2024 (as amended, the “JNJ License and Collaboration Agreement”). Pursuant to the JNJ License and Collaboration Agreement, we were primarily responsible for the discovery, IND-enabling studies and the initial Phase 1 study for Icotyde, and JNJ is primarily responsible for conducting all further development.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
If we exercise our opt-out right, Takeda will have an exclusive worldwide license to develop and commercialize rusfertide, and we will receive royalties of 14% to 29% on annual worldwide net sales, with a weighted average royalty rate of 21% at $1.5 billion in net sales and a rate of 29% for net sales over $1.5 billion. In addition, under the agreement, we are eligible to receive up to an aggregate of $975.0 million in development, regulatory and sales milestones, including the $25.0 million milestone payment already received in September 2025, and up to $400.0 million in payments for exercising the opt-out right. Upcoming potential development milestones and potential sales milestones under the agreement if we exercise our opt-out right include the following:
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
If we do not exercise our opt-out right, we will be eligible to receive up to an aggregate of $305.0 million in development, regulatory and sales milestones and will continue sharing equally in profits and losses associated with rusfertide in the United States. In addition, we will receive tiered royalties ranging from 10% to 17% on ex-U.S. net sales of rusfertide.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, the One Big Beautiful Bill Act, which includes comprehensive U.S. corporate tax legislation, was enacted. The legislation includes the extension and modification of provisions originally introduced under the Tax Cuts and Jobs Act of 2017 and the introduction of new provisions. Key provisions include the restoration of bonus depreciation allowances, changes to the limitations on deductibility of business interest expense, and the reintroduction of immediate expensing of U.S. research and development costs. The impact of the tax law changes on current and deferred taxes is reported in continuing operations in the interim period that includes the enactment date. See Note 13 to the Consolidated Financial Statements included elsewhere in this Annual Report for additional information.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
We do not have any commercialized products, and our revenue is derived from licensing and collaboration agreements. As described above, we have the right under the Takeda Collaboration Agreement to opt-out of the US profit and loss sharing arrangement. We currently expect to exercise that right in the second quarter of 2026 and, if we exercise that right, will be eligible to receive up to $400.0 million in payments, along with an enhanced milestone payment of $75.0 million upon the FDA’s approval of rusfertide. In addition, we may also receive royalties in 2026 from the launch of Icotyde and rusfertide, if they obtain FDA approval.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedMD&A
We are a discovery through late-stage development biopharmaceutical company focused on peptide therapeutics. Our clinical programs fall into two broad categories of diseases: (i) hematology and blood disorders, and (ii) inflammatory and immunomodulatory (“I&I”) diseases. Two novel peptides derived from our proprietary discovery technology platform, rusfertide and icotrokinra (formerly known as JNJ-2113), are currently in advanced Phase 3 clinical development, with New Drug Application (“NDA”) submissions to the U.S. Food and Drug Administration (“FDA”) potentially in 2025.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
Rusfertide, an injectable mimetic of the natural hormone hepcidin, is currently in Phase 3 development for treatment of the rare blood disorder polycythemia vera (“PV”). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals, Inc. (“Takeda”) and the Company remains primarily responsible for development through NDA filing. Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) and is licensed to J&J Innovative Medicines (“JNJ”), formerly Janssen Biotech, Inc. Following icotrokinra’s joint discovery by us and JNJ scientists pursuant to our IL-23R collaboration, we were primarily responsible for the development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
Rusfertide is currently in Phase 3 development for the treatment of PV. VERIFY (ClinicalTrials.gov identifier NCT05210790) is a global double-blind, placebo-controlled Phase 3 clinical trial of rusfertide in PV for approximately 250 patients. The trial evaluates the efficacy, symptom burden and safety of once-weekly, subcutaneously self-administered rusfertide in patients with uncontrolled hematocrit who are phlebotomy dependent despite standard of care treatment. The trial enrolled patients across North and South America, Europe, Asia and Australia. We expect to announce top-line data for the trial’s 32-week primary efficacy endpoint in March 2025, potentially leading to an NDA filing in the fourth quarter of 2025.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
REVIVE (NCT04057040) – A Phase 2 proof of concept (“POC”) trial, was initiated in the fourth quarter of 2019. We completed enrollment of patients in the first quarter of 2022 and 70 patients were enrolled through the end of the randomized withdrawal portion of the trial, which was completed during the first quarter of 2023 and is continuing in an ongoing open-label extension (“OLE”);
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
THRIVE (NCT06033586) – A Phase 2 long-term OLE for REVIVE patients on years three through five of treatment; and
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
PACIFIC (NCT04767802) – Another Phase 2 trial for rusfertide for patients diagnosed with PV and with routinely elevated hematocrit levels (>48%), was initiated during the first quarter of 2021, and the 52-week trial was completed during the second quarter of 2023.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
Final results from the REVIVE trial presented at the American Society of Hematology (“ASH”) 2024 Annual Meeting in December 2024 showed that 54% of patients with PV experienced more than 2.5 years of durable hematocrit control (<45%), decreased phlebotomy use, long-term tolerability and improvements in patient-reported outcomes.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
$25.0 million upon successful achievement of the primary endpoint in the Phase 3 VERIFY trial for rusfertide in PV; and
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
$50.0 million upon FDA approval of an NDA for rusfertide in PV (or $75.0 million if we exercise our full right to opt-out of the 50:50 U.S. profit and loss sharing arrangement).
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
Our IL-23R antagonist compound icotrokinra, licensed to J&J, is an orally delivered drug that is designed to block biological pathways currently targeted by marketed injectable antibody drugs. Our orally stable peptide approach may offer a targeted therapeutic approach for gastrointestinal and systemic compartments as needed. We believe that, compared to antibody drugs, icotrokinra has the potential to provide clinical improvement in an oral medication with increased convenience and compliance and the opportunity for the earlier introduction of targeted oral therapy.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
ICONIC-LEAD (NCT06095115) – A 684-patient randomized, controlled Phase 3 trial to evaluate the safety and efficacy of icotrokinra compared with placebo in participants with moderate-to-severe plaque psoriasis, with PASI-90 (90% improvement in skin lesions as measured by the Psoriasis Area and Severity Index (“PASI”) and Investigator’s Global Assessment (“IGA”) scores of 0 (clear) or 1 (almost clear) as co-primary endpoints;
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
ICONIC-TOTAL (NCT06095102) – A 311-patient randomized, controlled Phase 3 trial to evaluate the efficacy and safety of icotrokinra compared with placebo for the treatment of plaque psoriasis in participants with at least moderate severity affecting special areas (scalp, genital, and/or palms of the hands and soles of the feet) with overall IGA scores of 0 or 1 as the primary endpoint;
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RewordedMD&A
Takeda Collaboration Agreement License and collaboration revenue of $269.4 million for the year ended December 31, 2024 2025 of $46.0 million related to the Takeda Collaboration Agreement and was comprised of (i) $254.1 $21.3 million representing a portion of the $300.0 $25.0 million upfront cash milestone payment received in September 2025 that was allocated to the delivery of the rusfertide license to Takeda upon effectiveness of delivery performance obligation under the agreement in March 2024, and (ii) $15.3 $24.7 million allocated to for development services provided by us during the period based on the cost cost-based input method.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We have a pre-clinical stage program to identify In December 2025, we nominated development candidate PN-8047, an orally administered hepcidin mimetic/ferroportin blocker, functional mimetic small molecule, which we believe to may be complementary to the injectable rusfertide for offering the best treatment options for PV and other potential erythropoietic and iron imbalance disorders, and we expect to nominate a development candidate in the fourth quarter of 2025. PV.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The $254.4 $126.5 million increase decrease in cash provided by operating activities during the year ended December 31, 2024, 2025, as compared to the year ended December 31, 2023, 2024, was primarily due to the receipt of a $300.0 million one-time, non-refundable upfront payment related to upon the effectiveness of the Takeda Collaboration Agreement. Agreement in 2024, partially offset by the receipt of the $165.0 million milestone payment from JNJ and the $25.0 million milestone payment from Takeda in 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
This increase was primarily due to a $2.9 million increase in stock-based compensation expense and an increase of $2.6 million in professional services expenses, partially offset by $4.6 million increase in advisory and legal fees incurred during the year ended December 31, 2024 related to the Takeda Collaboration agreement and a $4.4 million increase in stock-based compensation expense. Agreement.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
These changes were partially offset The $3.0 million decrease in cash provided by financing activities for year ended December 31, 2025, as compared to the year ended December 31, 2024, was primarily due to a $21.7 $3.1 million increase decrease in proceeds from the issuance of common stock upon exercise of options and purchases of common stock under our ESPP.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
We expect our research and development expenses to increase in the near term as compared to prior year periods as we continue to focus our resources toward (i) progressing our rusfertide program into late stage clinical trials and preparing for regulatory filings and commercialization, and (ii) advancing our pre-clinical and drug discovery research and clinical programs, including progressing our recently nominated product development candidate PN-881 candidates PN-881, PN-477, PN-458 and PN-8047 through IND-enabling studies, or foreign equivalents.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by operating activities for the year ended December 31, 2024 2025 was $184.2 $57.7 million and consisted primarily of our a net income change of $275.2 $146.2 million in net operating assets and liabilities and certain non-cash items, including $37.6 $46.0 million of stock-based compensation, partially offset by a net change loss of $122.6 $130.1 million in net operating assets and liabilities. during the period.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
There has been uncertainty and disruption in the global economy and financial markets due to a number of factors, including but not limited to geopolitical instability, inflationary pressures, high interest rates, a recessionary environment, domestic and global monetary and fiscal policy, changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, banking actions and other financial institution instability and other factors. retaliatory actions.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
The change in net operating assets and liabilities was driven primarily by a change of $155.0 $165.0 million in receivable from a collaboration partner related to a milestone payment received under the JNJ License and Collaboration Agreement, partially offset by a $21.0 million change of $30.6 million in deferred revenue related to the Takeda Collaboration Agreement. revenue.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Takeda Collaboration Agreement License and collaboration revenue of $269.4 million for the year ended December 31, 2024 was comprised of $434.4 million included (i) $254.1 million of the $300.0 million upfront cash payment allocated to the delivery of the rusfertide license to Takeda upon effectiveness of the agreement Takeda Collaboration Agreement in March 2024, and (ii) $15.3 million allocated to development services provided by us during the period based on the cost input method. method under the Takeda Collaboration Agreement
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
General and administrative expenses increased $10.0 $1.4 million, or 30%, 3%, from $33.5 million for the year ended December 31, 2023 to $43.5 million for the year ended December 31, 2024. 2024 to $44.9 million for the year ended December 31, 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Interest income increased $11.4 $2.5 million, or 77%, 9%, from $14.9 million for the year ended December 31, 2023 to $26.3 million for the year ended December 31, 2024. 2024 to $28.8 million for the year ended December 31, 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new